Buy Timken India; target of Rs 640: ICICI Direct

ICICI Direct's research report on Timken India

Timken India (TIL) reported strong Q3FY19 numbers. TIL is now reporting merged entity numbers, i.e. Timken + (erstwhile) ABC Bearings For Q3FY19, revenues came in at Rs 384.9 crore, up 38.1% YoY. We expected revenues of Rs 349.2 crore (25% growth) Gross margins were at 45.6% vs. 36.9% YoY. EBITDA margins were at 14.4% vs. 7.4 YoY. Gross margins, EBITDA margins were lower in Q3FY18 due to a change in product mix and high input prices during the quarter. We believe the same has now corrected in Q3FY19 Accordingly, absolute EBITDA and PAT grew 168.1% and 188.2% to Rs 55.6 crore and Rs 26.4 crore, respectively.

Outlook

We expect strong EBITDA growth as we estimate utilisation of 75% and 80% in FY20E and FY21E, respectively. We value the company at 29x FY21E EPS to arrive at target price of Rs 640. We maintain BUY rating on the company.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Feb 25, 2019 04:06 pm

Hot Growth Stocks To Own For 2019

tags:BWLD,TBI,ISRG,JWN,MED,

Going to college promises the opportunity to further your education, meet new people and get a taste of independence. It does not guarantee a lucrative career after graduation. While it's true that a worker with a bachelor's degree typically earns 67.7% more than someone with just a high school diploma, according to the U.S. Bureau of Labor Statistics, what you study can be a better indicator of your future employability and earnings potential.

We analyzed data for 215 popular college majors, looking at the typical starting and mid-career salaries expected from each. We also examined recent online job postings seeking candidates with those majors, as well as long-term growth expectations for related occupations, to determine hiring demand in these fields.

Hot Growth Stocks To Own For 2019: Buffalo Wild Wings Inc.(BWLD)

Advisors' Opinion:

• [By Peter Graham]

  A long term performance chart shows Dave & Busters Entertainment tripling in value before falling back while small cap upscale gentlemen's clubs and restaurant owner RCI Hospitality Holdings, Inc (NASDAQ: RICK) began taking off in 2016 and small cap Buffalo Wild Wings (NASDAQ: BWLD) is being acquired by Arby's Restaurant Group:

• [By Steve Symington]

  That's not to say it was a quiet day for every stock on the market. With earnings season ramping up, brewing giant Anheuser-Busch InBev (NYSE:BUD) and restaurant chain Buffalo Wild Wings (NASDAQ:BWLD) served as an exercise in contrast as investors reacted to their respective quarterly reports.

Hot Growth Stocks To Own For 2019: TrueBlue Inc.(TBI)

Advisors' Opinion:

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Trueblue (TBI)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Trueblue Inc (NYSE:TBI) by 18.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,550 shares of the business services provider’s stock after purchasing an additional 4,700 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Trueblue were worth $823,000 as of its most recent filing with the Securities & Exchange Commission.

• [By Logan Wallace]

  Media stories about Trueblue (NYSE:TBI) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trueblue earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the business services provider an impact score of 45.3296498009881 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

• [By Stephan Byrd]

  Russell Investments Group Ltd. grew its stake in Trueblue Inc (NYSE:TBI) by 21.2% during the first quarter, HoldingsChannel reports. The fund owned 137,178 shares of the business services provider’s stock after purchasing an additional 23,951 shares during the quarter. Russell Investments Group Ltd.’s holdings in Trueblue were worth $3,553,000 at the end of the most recent quarter.

• [By Motley Fool Transcribers]

  TrueBlue Inc  (NYSE:TBI)Q4 2018 Earnings Conference CallFeb. 07, 2019, 5:00 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

Hot Growth Stocks To Own For 2019: Intuitive Surgical Inc.(ISRG)

Advisors' Opinion:

• [By Motley Fool Staff]

  Stock No. 4: Let's go to the "I" stock from our April stocks a year ago. That's one of my favorite companies, a stock that I own, and have held for more than a decade, and that would be Intuitive Surgical (NASDAQ:ISRG), the maker of the da Vinci robot, the surgical robot.

• [By Stephan Byrd]

  Align Technology (NASDAQ: ALGN) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

• [By ]

  As of the time of this article, home cleaning robot maker iRobot's (IRBT) shares are down over 6% on the news. And though it makes surgical robots rather than anything meant for homes, Intuitive Surgical  (ISRG) is down close to 2%. As usual, Wall Street immediately trembles on any sign that Amazon plans to further expand its reach.

• [By Garrett Baldwin]

  Earnings season is well underway. And if you're looking to make real money, the time to get started is now. Money Morning Quantitative Specialist Chris Johnson argues the markets are at a tipping point. And with just a few smart plays in today's classic stock picker's market… you can pull in triple-digit gains with just a small investment. Read those picks right here.

  The Top Stock Market Stories for Thursday This morning, the U.S. Department of Labor said that weekly jobless claims came in at 207,000 for the week. That figure is below the 220,000 jobless claims expected by economists and brings U.S. unemployment claims to a 48.5-year low. It's a big day of earnings reports, as dozens of blue chip companies will report results from the June-ending quarter. The biggest name today will be Microsoft Corp. (Nasdaq: MSFT), which reports earnings after the bell. Wall Street expects that the technology giant will report earnings of $1.07 per share. Analysts project quarterly revenue of $29.17 billion. Three Stocks to Watch Today: PM, IBM, AA International Business Machines (NYSE: IBM) stock added 2.5% in pre-market hours after Big Blue topped Wall Street earnings and revenue expectations. The tech giant continues to post positive results as it accelerates its turnaround efforts. IBM reported earnings per share of $3.08, a figure that beat estimates by $0.04 per share. It also reported quarterly revenue of $20.0 billion, a figure that surpassed estimates of $19.85 billion. Shares of Alcoa Corp. (NYSE: AA) fell 2% this morning. The aluminum manufacturer slashed its 2018 outlook due to falling prices and the recent round of metals tariffs introduced by the Trump administration. But there could be more pain in sight. Today, the U.S. Justice Department will hold a hearing that aims to determine whether vehicle and light truck imports present a national security threat to the United States. The hearing is due to President Trump's pledge to hit European auto man
• [By Brian Feroldi]

  TransEnterix (NYSEMKT:TRXC) recently surprised investors on the upside when it reported its first-quarter results. The company's Senhance surgical system is off to a fast start right out of the gate, and it has attracted a lot of positive attention from the medical community. This just goes to show how much demand is out there for an alternative to Intuitive Surgical's (NASDAQ: ISRG) dominant da Vinci platform. 

• [By Motley Fool Transcribing]

  Intuitive Surgical (NASDAQ:ISRG) Q4 2018 Earnings Conference CallJan. 24, 2019 4:30 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

Hot Growth Stocks To Own For 2019: Nordstrom Inc.(JWN)

Advisors' Opinion:

• [By Chris Lange]

  Nordstrom Inc. (NYSE: JWN) will reveal its fiscal fourth-quarter results later Thursday. The consensus analyst estimates are $1.42 in EPS and revenue of $4.61 billion. Shares of Nordstrom closed at $44.04 on Friday, while the consensus price target is $52.00. The 52-week range is $43.04 to $67.75.

• [By JJ Kinahan]

  DE was the second company to disappoint the Street since yesterday’s closing bell. Retailer Nordstrom, Inc. (NYSE: JWN) beat Wall Street analysts’ earnings per share estimates and raised guidance, but missed on same-store sales. That key metric barely rose (up 0.2 percent), and shares of JWN tumbled more than 6 percent in pre-market futures trading. The same-store weakness for JWN came after a bunch of other retailers reported growth in that area.

• [By Douglas A. McIntyre]

  Nordstrom Inc. (NYSE: JWN) may reopen plans for a leveraged buyout after good holiday results. According to The Wall Street Journal:

  The failed effort by the Nordstrom family to take the namesake department store chain private will be remembered as a missed opportunity amid the selloff in retailers' stocks last fall.

• [By Motley Fool Staff]

  In this clip, host Chris Hill and Motley Fool contributor Ron Gross go through the most important numbers and trends from Nordstrom (NYSE:JWN), Macy's (NYSE:M), and JC Penney (NYSE:JCP), explain why the stocks went in the directions they did after reports came out, and take a peek at the long-term health of each mall-based retailer.

Hot Growth Stocks To Own For 2019: MEDIFAST INC(MED)

Advisors' Opinion:

• [By Max Byerly]

  MediBloc (CURRENCY:MED) traded 0.2% lower against the U.S. dollar during the twenty-four hour period ending at 16:00 PM Eastern on June 7th. MediBloc has a total market cap of $37.92 million and $586,074.00 worth of MediBloc was traded on exchanges in the last 24 hours. Over the last week, MediBloc has traded down 36% against the U.S. dollar. One MediBloc token can now be purchased for $0.0128 or 0.00000166 BTC on major exchanges including Coinrail, Bibox and Gate.io.

• [By Lisa Levin] Gainers Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares rose 35.8 percent to $3.00. Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares surged 32 percent to $8.94 after reporting upbeat Q1 earnings. Carbon Black, Inc. (NASDAQ: CBLK) gained 29.6 percent to $24.62. Carbon Black priced its IPO at $19 per share. California Resources Corporation (NYSE: CRC) shares rose 26.8 percent to $32.70 following upbeat Q1 earnings. Pandora Media, Inc. (NYSE: P) gained 25 percent to $7.185 after reporting strong quarterly results. Medifast, Inc. (NYSE: MED) shares climbed 23.7 percent to $122.87 after the company reported strong Q1 results and raised its FY18 guidance. Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.2 percent to $8.4999 after reporting Q2 results. Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) gained 22.2 percent to $41.27 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban. Shake Shack Inc (NYSE: SHAK) rose 22.2 percent to $57.955 after the company reported upbeat results for its first quarter and raised its FY18 guidance. Atomera Incorporated (NASDAQ: ATOM) jumped 19.7 percent to $6.12 after reporting Q1 results. Super Micro Computer, Inc. (NASDAQ: SMCI) rose 16.4 percent to $21.00 after reporting strong preliminary results for the third quarter. Titan International, Inc. (NYSE: TWI) shares rose 16.4 percent to $12.21 following Q1 earnings. Integer Holdings Corporation (NYSE: ITGR) shares gained 14.9 percent to $63.75 following Q1 results. Control4 Corporation (NASDAQ: CTRL) shares climbed 14.5 percent to $23.98 folloiwng strong Q1 results. B&G Foods, Inc. (NYSE: BGS) climbed 12.6 percent to $25.40 after reporting Q1 earnings. HMS Holdings Corp (NASDAQ: HMSY) shares gained 10 percent to $19.59 after reporting upbeat quarterly earnings. Viavi Solutions Inc. (NASDAQ: VIAV) rose 7 percent to $10.09 following Q3 r
• [By Joseph Griffin]

  MediBloc [QRC] (MED) is a proof-of-work (PoW) token that uses the HybridScryptHash256 hashing algorithm. Its genesis date was January 3rd, 2014. MediBloc [QRC]’s total supply is 4,097,545,844 tokens and its circulating supply is 2,966,384,100 tokens. The official website for MediBloc [QRC] is medibloc.org/en. MediBloc [QRC]’s official Twitter account is @MEDDevTeam. The Reddit community for MediBloc [QRC] is /r/MediBloc and the currency’s Github account can be viewed here. The official message board for MediBloc [QRC] is medium.com/@MediBloc.

Seaport Global Securities Weighs in on ChoicePoint Inc.’s Q1 2019 Earnings (CPS)

ChoicePoint Inc. (NYSE:CPS) – Analysts at Seaport Global Securities cut their Q1 2019 earnings estimates for shares of ChoicePoint in a note issued to investors on Monday, February 18th. Seaport Global Securities analyst M. Ward now forecasts that the auto parts company will post earnings of $1.37 per share for the quarter, down from their previous forecast of $1.91. Seaport Global Securities has a “Neutral” rating on the stock. Seaport Global Securities also issued estimates for ChoicePoint’s Q2 2019 earnings at $1.54 EPS, FY2019 earnings at $6.85 EPS, Q1 2020 earnings at $1.73 EPS and Q3 2020 earnings at $2.16 EPS.

Get ChoicePoint alerts:

ChoicePoint (NYSE:CPS) last announced its earnings results on Thursday, February 14th. The auto parts company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.93 by ($0.40). ChoicePoint had a return on equity of 17.95% and a net margin of 2.97%. The firm had revenue of $871.99 million for the quarter, compared to the consensus estimate of $894.65 million.

A number of other equities analysts also recently weighed in on CPS. ValuEngine downgraded shares of ChoicePoint from a “sell” rating to a “strong sell” rating in a research note on Friday, February 15th. Bank of America reaffirmed an “underperform” rating and issued a $40.00 price target (down from $63.00) on shares of ChoicePoint in a research note on Wednesday. Zacks Investment Research raised shares of ChoicePoint from a “strong sell” rating to a “hold” rating in a research note on Monday, January 7th. Roth Capital decreased their price target on shares of ChoicePoint from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, February 14th. Finally, Buckingham Research downgraded shares of ChoicePoint from a “buy” rating to a “neutral” rating and decreased their price target for the company from $140.00 to $76.00 in a research note on Monday, November 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $85.50.

Shares of NYSE CPS opened at $62.01 on Thursday. ChoicePoint has a twelve month low of $56.68 and a twelve month high of $146.77. The firm has a market cap of $1.10 billion, a P/E ratio of 7.05 and a beta of 1.46. The company has a quick ratio of 1.44, a current ratio of 1.53 and a debt-to-equity ratio of 0.85.

A number of institutional investors and hedge funds have recently bought and sold shares of CPS. SG Americas Securities LLC increased its stake in ChoicePoint by 1,300.4% in the fourth quarter. SG Americas Securities LLC now owns 45,388 shares of the auto parts company’s stock valued at $2,820,000 after purchasing an additional 42,147 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in ChoicePoint in the third quarter valued at $3,803,000. Seizert Capital Partners LLC grew its holdings in shares of ChoicePoint by 59.8% during the fourth quarter. Seizert Capital Partners LLC now owns 44,703 shares of the auto parts company’s stock valued at $2,777,000 after buying an additional 16,720 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of ChoicePoint by 22.0% during the fourth quarter. Rhumbline Advisers now owns 50,222 shares of the auto parts company’s stock valued at $3,120,000 after buying an additional 9,061 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its holdings in shares of ChoicePoint by 356.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,809 shares of the auto parts company’s stock valued at $361,000 after buying an additional 4,537 shares during the last quarter. 95.47% of the stock is owned by hedge funds and other institutional investors.

About ChoicePoint

Cooper-Standard Holdings Inc, through its subsidiary, Cooper-Standard Automotive Inc, designs, manufactures, and sells sealing, fuel and brake delivery, fluid transfer, and anti-vibration systems worldwide. It operates in four segments: North America, Europe, Asia Pacific, and South America. The company's sealing systems include dynamic and static seals, encapsulated glasses, stainless steel trims, flush glass systems, variable extrusions, and specialty sealing products.

Further Reading: How a Strangle Strategy is different from a Straddle Strategy

IncaKoin 24-Hour Trading Volume Reaches $0.00 (NKA)

IncaKoin (CURRENCY:NKA) traded flat against the U.S. dollar during the twenty-four hour period ending at 22:00 PM ET on February 19th. IncaKoin has a total market capitalization of $194,432.00 and approximately $0.00 worth of IncaKoin was traded on exchanges in the last 24 hours. One IncaKoin coin can now be purchased for $0.0000 or 0.00000000 BTC on popular cryptocurrency exchanges including Cryptopia and Trade Satoshi. During the last seven days, IncaKoin has traded flat against the U.S. dollar.

Here is how similar cryptocurrencies have performed during the last 24 hours:

Get IncaKoin alerts: Dash (DASH) traded 1.5% lower against the dollar and now trades at $86.61 or 0.02189632 BTC. Decred (DCR) traded 0.2% higher against the dollar and now trades at $17.46 or 0.00441385 BTC. Bitcoin Diamond (BCD) traded 0.3% lower against the dollar and now trades at $0.77 or 0.00019388 BTC. Aeternity (AE) traded down 1.9% against the dollar and now trades at $0.43 or 0.00010875 BTC. Hshare (HSR) traded 29.9% lower against the dollar and now trades at $2.26 or 0.00034804 BTC. Stratis (STRAT) traded 2.3% higher against the dollar and now trades at $0.90 or 0.00022770 BTC. PIVX (PIVX) traded 3.3% higher against the dollar and now trades at $0.79 or 0.00020082 BTC. ReddCoin (RDD) traded up 3.9% against the dollar and now trades at $0.0013 or 0.00000032 BTC. Enigma (ENG) traded 0.3% lower against the dollar and now trades at $0.33 or 0.00008245 BTC. BitcoinDark (BTCD) traded flat against the dollar and now trades at $16.23 or 0.00246929 BTC.

IncaKoin Profile

NKA is a PoW/PoS coin that uses the
SHA-256 hashing algorithm. It launched on January 23rd, 2015. IncaKoin’s total supply is 17,939,725,045 coins and its circulating supply is 17,937,725,045 coins. IncaKoin’s official website is incakoin.info. IncaKoin’s official Twitter account is @incakoin1 and its Facebook page is accessible here.

IncaKoin Coin Trading

IncaKoin can be traded on the following cryptocurrency exchanges: Cryptopia and Trade Satoshi. It is usually not possible to purchase alternative cryptocurrencies such as IncaKoin directly using U.S. dollars. Investors seeking to acquire IncaKoin should first purchase Ethereum or Bitcoin using an exchange that deals in U.S. dollars such as Coinbase, Changelly or GDAX. Investors can then use their newly-acquired Ethereum or Bitcoin to purchase IncaKoin using one of the aforementioned exchanges.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “NKAUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Michael Henrichsen Sells 100,000 Shares of Auryn Resources Inc (AUG) Stock

Auryn Resources Inc (TSE:AUG) Senior Officer Michael Henrichsen sold 100,000 shares of the business’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of C$1.31, for a total value of C$131,000.00. Following the completion of the sale, the insider now directly owns 201,000 shares of the company’s stock, valued at approximately C$263,310.

TSE AUG opened at C$1.40 on Wednesday. Auryn Resources Inc has a 1-year low of C$1.14 and a 1-year high of C$1.94. The stock has a market capitalization of $121.25 million and a PE ratio of 7.22.

Get Auryn Resources alerts:

ILLEGAL ACTIVITY NOTICE: “Michael Henrichsen Sells 100,000 Shares of Auryn Resources Inc (AUG) Stock” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4165014/michael-henrichsen-sells-100000-shares-of-auryn-resources-inc-aug-stock.html.

Auryn Resources Company Profile

Auryn Resources Inc, a junior mining exploration company, engages in the acquisition, exploration, and development of mineral resource properties. Its principal mineral properties are the Committee Bay gold project located in Nunavut, Canada and the Homestake Ridge project located within the Iskut-Stewart-Kitsault belt, in northwestern British Columbia.

Featured Story: Why Dividend Stocks May Be Right for You

United Technologies Co. (UTX) Expected to Post Quarterly Sales of $18.03 Billion

Analysts expect that United Technologies Co. (NYSE:UTX) will post $18.03 billion in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for United Technologies’ earnings. The lowest sales estimate is $17.84 billion and the highest is $18.17 billion. United Technologies reported sales of $15.24 billion during the same quarter last year, which would suggest a positive year over year growth rate of 18.3%. The business is expected to announce its next earnings report on Tuesday, April 23rd.

According to Zacks, analysts expect that United Technologies will report full-year sales of $76.85 billion for the current financial year, with estimates ranging from $76.40 billion to $77.31 billion. For the next financial year, analysts expect that the company will post sales of $80.05 billion, with estimates ranging from $79.35 billion to $80.61 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for United Technologies.

Get United Technologies alerts:

United Technologies (NYSE:UTX) last released its quarterly earnings data on Wednesday, January 23rd. The conglomerate reported $1.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.53 by $0.42. The firm had revenue of $18.04 billion for the quarter, compared to analyst estimates of $16.87 billion. United Technologies had a net margin of 7.92% and a return on equity of 17.53%. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.60 earnings per share.

A number of analysts recently issued reports on UTX shares. Zacks Investment Research raised shares of United Technologies from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a report on Wednesday, January 30th. Royal Bank of Canada increased their price target on shares of United Technologies to $129.00 and gave the stock a “sector perform” rating in a report on Thursday, January 24th. Robert W. Baird lowered their price target on shares of United Technologies from $167.00 to $149.00 and set an “outperform” rating on the stock in a report on Wednesday, November 28th. Bank of America set a $180.00 price target on shares of United Technologies and gave the stock a “buy” rating in a report on Tuesday, November 27th. Finally, OTR Global downgraded shares of United Technologies to a “positive” rating in a report on Friday, January 18th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $144.85.

In other United Technologies news, EVP Michael R. Dumais sold 9,620 shares of the stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $119.12, for a total transaction of $1,145,934.40. Following the transaction, the executive vice president now directly owns 35,627 shares of the company’s stock, valued at $4,243,888.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Robert J. Bailey sold 862 shares of the stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $121.71, for a total transaction of $104,914.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,355 shares of company stock worth $8,538,419. Insiders own 0.17% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in United Technologies by 1.9% during the third quarter. Vanguard Group Inc. now owns 59,240,301 shares of the conglomerate’s stock worth $8,282,386,000 after purchasing an additional 1,094,947 shares during the last quarter. Vanguard Group Inc increased its position in United Technologies by 1.9% during the third quarter. Vanguard Group Inc now owns 59,240,301 shares of the conglomerate’s stock worth $8,282,386,000 after purchasing an additional 1,094,947 shares during the last quarter. BlackRock Inc. increased its position in United Technologies by 13.3% during the fourth quarter. BlackRock Inc. now owns 54,035,145 shares of the conglomerate’s stock worth $5,753,662,000 after purchasing an additional 6,347,718 shares during the last quarter. FMR LLC increased its position in United Technologies by 1.4% during the third quarter. FMR LLC now owns 26,833,527 shares of the conglomerate’s stock worth $3,751,597,000 after purchasing an additional 372,456 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in United Technologies by 0.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 15,219,419 shares of the conglomerate’s stock worth $1,620,563,000 after purchasing an additional 61,785 shares during the last quarter. 83.48% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:UTX traded up $3.63 during midday trading on Friday, reaching $127.76. The company’s stock had a trading volume of 6,828,359 shares, compared to its average volume of 5,218,813. The firm has a market capitalization of $110.10 billion, a P/E ratio of 16.79, a PEG ratio of 1.79 and a beta of 1.17. United Technologies has a twelve month low of $100.48 and a twelve month high of $144.15. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.13 and a quick ratio of 0.81.

The business also recently disclosed a quarterly dividend, which will be paid on Sunday, March 10th. Shareholders of record on Friday, February 15th will be issued a dividend of $0.735 per share. This represents a $2.94 annualized dividend and a yield of 2.30%. The ex-dividend date of this dividend is Thursday, February 14th. United Technologies’s payout ratio is 38.63%.

About United Technologies

United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. Its Otis segment designs, manufactures, sells, and installs passenger and freight elevators, escalators, and moving walkways; and offers modernization products to upgrade elevators and escalators, as well as maintenance and repair services.

Read More: How Investors Can Profit from Options Trading

Get a free copy of the Zacks research report on United Technologies (UTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Corporate Office Properties Trust (OFC) Cut to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Corporate Office Properties Trust (NYSE:OFC) from a hold rating to a sell rating in a research report released on Saturday.

According to Zacks, “Corporate Office Properties Trust is a fully-integrated and self-managed real estate investment trust that focuses principally on the ownership, management, leasing, acquisition and development of suburban office buildings located in select submarkets in the Mid-Atlantic region of the United States. Corporate Office Properties operates three real estate service companies: Corporate Development Services, Corporate Office Services and Corporate Management Services. “

Get Corporate Office Properties Trust alerts:

Other equities analysts have also issued reports about the stock. Robert W. Baird upgraded shares of Corporate Office Properties Trust from a neutral rating to an outperform rating in a research report on Tuesday, January 8th. ValuEngine lowered shares of Corporate Office Properties Trust from a hold rating to a sell rating in a research report on Friday, November 16th. Wells Fargo & Co set a $25.00 price objective on shares of Corporate Office Properties Trust and gave the company a market perform rating in a research report on Wednesday, January 16th. They noted that the move was a valuation call. Bank of America lowered shares of Corporate Office Properties Trust from a buy rating to a neutral rating and lowered their price objective for the company from $31.00 to $27.00 in a research report on Friday, November 30th. Finally, Stifel Nicolaus raised Corporate Office Properties Trust from a sell rating to a hold rating and set a $22.00 target price for the company in a report on Thursday, January 3rd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. Corporate Office Properties Trust currently has a consensus rating of Hold and an average target price of $27.00.

NYSE:OFC traded up $0.31 during midday trading on Friday, reaching $26.16. The stock had a trading volume of 707,401 shares, compared to its average volume of 783,416. Corporate Office Properties Trust has a 12-month low of $20.03 and a 12-month high of $31.01. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.95 and a quick ratio of 1.92. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of 13.01, a price-to-earnings-growth ratio of 2.58 and a beta of 1.04.

Corporate Office Properties Trust (NYSE:OFC) last posted its quarterly earnings data on Thursday, February 7th. The real estate investment trust reported $0.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.50. Corporate Office Properties Trust had a net margin of 12.49% and a return on equity of 4.64%. The firm had revenue of $138.48 million for the quarter, compared to analyst estimates of $152.94 million. During the same period last year, the firm posted $0.53 EPS. Corporate Office Properties Trust’s quarterly revenue was down 15.9% on a year-over-year basis. As a group, analysts expect that Corporate Office Properties Trust will post 2.05 earnings per share for the current fiscal year.

In other Corporate Office Properties Trust news, Director Robert L. Denton sold 1,500 shares of the firm’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $25.65, for a total value of $38,475.00. Following the completion of the sale, the director now owns 280,000 shares of the company’s stock, valued at $7,182,000. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Stephen E. Budorick bought 4,023 shares of Corporate Office Properties Trust stock in a transaction on Monday, November 19th. The stock was acquired at an average cost of $24.90 per share, with a total value of $100,172.70. Following the acquisition, the chief executive officer now owns 110,528 shares of the company’s stock, valued at approximately $2,752,147.20. The disclosure for this purchase can be found here. In the last three months, insiders acquired 17,243 shares of company stock valued at $395,348. 0.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its stake in shares of Corporate Office Properties Trust by 142.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,700 shares of the real estate investment trust’s stock worth $36,000 after buying an additional 1,000 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of Corporate Office Properties Trust by 2,069.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 864,333 shares of the real estate investment trust’s stock worth $41,000 after buying an additional 824,484 shares during the last quarter. Fort L.P. raised its stake in shares of Corporate Office Properties Trust by 420.6% during the 4th quarter. Fort L.P. now owns 2,150 shares of the real estate investment trust’s stock worth $45,000 after buying an additional 1,737 shares during the last quarter. Quantamental Technologies LLC acquired a new position in shares of Corporate Office Properties Trust during the 4th quarter worth $91,000. Finally, Private Advisor Group LLC acquired a new position in shares of Corporate Office Properties Trust during the 3rd quarter worth $210,000. 97.47% of the stock is owned by institutional investors.

Corporate Office Properties Trust Company Profile

COPT is a REIT that owns, manages, leases, develops and selectively acquires office and data center properties in locations that support the United States Government and its contractors, most of whom are engaged in national security, defense and information technology (?IT?) related activities servicing what it believes are growing, durable, priority missions (?Defense/IT Locations?).

Further Reading: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on Corporate Office Properties Trust (OFC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Short-seller Chanos says he will support Biden if he runs for president in 2020

Famed short-seller and Democratic donor Jim Chanos plans to support former vice president Joe Biden if he runs for president in 2020.

"Like many other Americans, I certainly hope Vice President Biden decides to run in 2020. If he does run, I fully expect to support him any way I can," Chanos said in a statement first given to CNBC.

When asked how much he is looking to spend to support a potential Biden candidacy, Chanos first responded, "lol no comment," and added: "Let's see if he decides to run, first."

A spokesman for Biden declined to comment.

Chanos, a longtime friend of Biden's, planned to support the former Delaware senator last time he was mulling a run for president ahead of the 2016 election. Chanos did not give to Hillary Clinton's campaign, according to Federal Election Commission records.

Chanos, who founded Kynikos Associates, has a history of supporting Democratic candidates, potentially making him a key financial ally for Biden if the former vice president chooses to run for president in 2020.

Chanos reportedly hosted a $10,000 a plate fundraiser in March 2018 to benefit House Democrats during the midterm election campaign. Biden was the special guest at the event.

While records show Chanos gave minimally during the 2018 race, he donated just over $50,000 to President Barack Obama's Victory Fund during his 2012 re-election bid. The Democratic Congressional Campaign Committee in 2016 saw Chanos donate over $55,000 to their cause.

The records don't reflect the fundraisers or other efforts Chanos has made in the past behind the scenes to help Democrats get elected.

Biden has been in touch with donors about possibly running for president in 2020 and has privately acknowledged he's leaning toward entering the race, according to people with direct knowledge of the talks. Biden has not made a final decision.

Chanos would not say whether he has heard from Biden.

D-Street Buzz: Pharma stocks plunge with Dr Reddy's Labs at new 52-week low; BPCL jumps 3%

The Indian benchmark indices have extended the morning loses with the Nifty and Sensex down close to 1 percent each. Nifty50 fell 100 points, trading at 10646 while the Sensex fell 317 points and was trading at 35,558 mark.

The pharma sector was the underperforming sector, down over 4 percent dragged by Dr Reddy's Labs and Glenmark Pharma which fell 8 percent followed by Divis Labs, Lupin, Sun Pharma and Aurobindo Pharma.

Nifty midcap was down 2 percent with loses from Bank of India, Berger Paints, Bharat Forge, Century Textiles, Cummins India, DHFL, JSPL, M&M Financial Services, PAGE Industries, SRF and United Breweries among others.

From the metal space, the top losers were JSW Steel, Hindustan Copper, JSPL, SAIL and Tata Steel.

related news Buy or Sell | Strong support for Nifty at 10,750-10,780 Gross inflows into MFs dropped in Jan; 10 stocks that fund houses bought & sold Ashok Leyland slides 6% as axle load norms, political uncertainty may hit growth

Nifty Energy was trading in the green with gains from BPCL, GAIL India and ONGC.

From the infra space, the top gainers were Adani Power, Bharti Infratel, NBCC, GMR Infra, NTPC, Power Grid and Tata Power.

The top gainers from NSE included Bharti Infratel, Power Grid, NTPC BPCL and GAIL India while the top losers included Dr Reddy's Labs, JSW Steel, Sun Pharma, Grasim Industries and Hindalco Industries.

The most active stocks were YES Bank, Dr Reddy's Labs, ITC, Axis Bank and Reliance Industries.

Aditya Birla Fashion and Retail, Sagardeep Alloys, SKF India and Xelpmoc Design And Tech have hit new 52-week high in this afternoon session.

227 stocks have hit new 52-week low on the NSE including names like Balmer Lawrie & Company, Dr Reddy's Labs, Hindalco Industries, Cadila Healthcare, Castex Technologies, Cochin Shipyard, Gujarat State Petronet, Kitex Garments, Mahindra & Mahindra, Natco Pharma, Punj Lloyd, RAIN Industries, Rashtriya Chemicals and Fertilizers, Sagar Cements and Unitech among others.

The breadth of the market favoured the declines with 467 stocks advancing and 1204 declining while 385 remained unchanged. On the BSE, 697 stocks advanced, 1557 declined and 117 remained unchanged.

Disclosure: Reliance Industries Ltd. is the sole beneficiary of Independent Media Trust which controls Network18 Media & Investments Ltd.

For more market news, click here First Published on Feb 15, 2019 12:52 pm

Zacks: Analysts Anticipate Glaukos Corp (GKOS) Will Announce Quarterly Sales of $49.44 Million

Equities analysts predict that Glaukos Corp (NYSE:GKOS) will report $49.44 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Glaukos’ earnings, with estimates ranging from $48.40 million to $50.00 million. Glaukos posted sales of $41.65 million during the same quarter last year, which suggests a positive year-over-year growth rate of 18.7%. The company is scheduled to announce its next earnings report after the market closes on Wednesday, February 27th.

According to Zacks, analysts expect that Glaukos will report full year sales of $176.77 million for the current year, with estimates ranging from $175.60 million to $177.30 million. For the next financial year, analysts anticipate that the firm will report sales of $223.18 million, with estimates ranging from $214.86 million to $233.13 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Glaukos.

Get Glaukos alerts:

Separately, Zacks Investment Research cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, January 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $58.20.

GKOS stock opened at $68.00 on Tuesday. Glaukos has a 12 month low of $26.75 and a 12 month high of $70.91.

In other news, Director William J. Phd Link sold 41,500 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $57.62, for a total value of $2,391,230.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph E. Gilliam sold 2,100 shares of the stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $58.37, for a total transaction of $122,577.00. Following the completion of the sale, the chief financial officer now directly owns 91,117 shares of the company’s stock, valued at approximately $5,318,499.29. The disclosure for this sale can be found here. In the last three months, insiders sold 48,600 shares of company stock valued at $2,813,957. Corporate insiders own 11.60% of the company’s stock.

Several large investors have recently bought and sold shares of GKOS. Victory Capital Management Inc. purchased a new position in shares of Glaukos during the 4th quarter worth approximately $20,893,000. New York State Common Retirement Fund boosted its position in shares of Glaukos by 139.3% during the 4th quarter. New York State Common Retirement Fund now owns 510,458 shares of the medical instruments supplier’s stock worth $28,672,000 after purchasing an additional 297,158 shares during the period. FMR LLC boosted its position in shares of Glaukos by 16.2% during the 3rd quarter. FMR LLC now owns 1,227,430 shares of the medical instruments supplier’s stock worth $79,660,000 after purchasing an additional 171,268 shares during the period. BlackRock Inc. boosted its position in shares of Glaukos by 6.3% during the 4th quarter. BlackRock Inc. now owns 2,563,895 shares of the medical instruments supplier’s stock worth $144,014,000 after purchasing an additional 151,304 shares during the period. Finally, Baillie Gifford & Co. boosted its position in shares of Glaukos by 11.5% during the 3rd quarter. Baillie Gifford & Co. now owns 1,351,531 shares of the medical instruments supplier’s stock worth $87,714,000 after purchasing an additional 139,868 shares during the period.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Featured Story: Momentum Investing

Get a free copy of the Zacks research report on Glaukos (GKOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Will Pledges for 100% Carbon-Free Electricity Catch On in 2019?

Late last year, Xcel Energy (NASDAQ:XEL) became the first utility to publicly and boldly commit to generating all of its electricity from 100% carbon-free sources by 2050. While individuals and groups who take environmental stewardship seriously cheered the news, individual investors and Wall Street analysts should be cheering, too. 

Why? Publicly committing to such an ambitious long-term goal provides a good deal of certainty for the road ahead. That will benefit individual investors, especially considering few things are as detrimental to a stock as uncertainty. The advantage of mitigating future policy risks by going all-in on zero-carbon power, coupled with continually improving economics for renewable energy and an increased appetite for states to provide incentives for nuclear power, suggest other utilities will follow Xcel Energy.

Image source: Getty Images.

Xcel Energy's path to 100% carbon-free electricity

Amid the doom and gloom coverage of climate change in the news media, there are plenty of reasons for optimism. While there's room for smart policy changes to expedite the transition away from coal-fired power plants and toward cleaner energy sources, innovation and market forces actually have the power sector in the United States on pace to meet its climate pledges. In fact, half of electric utilities are well ahead of even the most optimistic decarbonization projections. Xcel Energy has been a shining example.

In 2005, the utility, which serves three states in the Southwest as well as five upper Midwestern states, relied on coal power for 56% of its electricity generation. Wind and solar, categorized as "modern renewables," made up just 3% of its generation mix that year. By 2017, the utility cut the share of coal in its portfolio to 37% and increased modern renewables to 23%. The 35% drop in carbon emissions from the 2005 baseline in that span exceeds the Paris Accord commitment of reducing carbon emissions 27% by 2025, and it exceeds the Environmental Protection Agency (EPA) Clean Power Plan goal of a 32% decline by 2030. 

Xcel Energy has no intention of easing up on its assault on more expensive and dirtier coal-fired power. The utility expects carbon emissions -- compared with 2005 -- to fall 45% by 2021, 80% by 2030, and 100% by 2050. The near-term targets aren't too surprising considering that the recently approved Colorado Energy Plan will shift the company's generation mix to just 19% coal and 46% modern renewables by 2027.

The longer-term targets are perhaps a little more surprising, as they suggest the utility will need to jettison natural-gas-fired power plants -- which will provide 21% of its electricity in 2027 -- from its portfolio. Current economics don't provide any easy ways to stop using the cleaner-burning fuel (natural gas emits half the carbon emissions as coal to generate an equal amount of electricity), although that could change in the coming decades if wind, solar, and energy storage continue to walk down the cost curve. And if Xcel Energy sees a path to zero natural gas, then so could some of its well-positioned peers.

Image source: Getty Images.

Who's next for a zero-carbon electricity pledge?

Xcel Energy's ambitious power plan is part of its "Steel for Fuel" strategy. That is, modern renewables can be more economical to operate than coal-fired and natural-gas-fired power plants, since wind and solar farms don't require fuel purchases to operate. NextEra Energy (NYSE:NEE) has a similar strategy for its lone electric utility franchise, Florida Power & Light.

The utility is powering ahead with its "30 by 30" strategy -- a pledge to install 30 million solar panels in Florida by 2030. NextEra Energy says that would result in 10,000 megawatts of solar power capacity, up from the entire state's 2,159 megawatts in operation today. Investors who can remember back to 2017 will notice how quickly the plans have changed. 

Way back then, Florida Power & Light had only committed to installing 10 million solar panels by 2023 and 2,100 megawatts of solar capacity by 2025. Improving economics have changed that overnight. NextEra recently said the four solar facilities coming online in Florida in 2019 cost one-third the price of facilities brought online just a few years ago. It has already sited an additional 100 facilities (yes, 100) for future expansion. 

While the current 30-by-30 strategy is encouraging, Florida faces challenges on the path to 100% carbon-free electricity. The American Southeast has virtually no wind potential, which explains why Florida has no wind turbines operating today (it may be able to generate 15% of its electric needs from offshore wind power, though). And although it's called the Sunshine State, Florida has salty and humid air that corrodes solar panels and saps efficiency. The challenges are why Florida Power & Light leans on natural gas and nuclear power for 73% and 25%, respectively, of its electricity generation. Solar power is currently just 2% of the utility's portfolio, no better than the national average.  

That said, three decades will pass between now and 2050, so forecasting market conditions, technology improvements, and societal changes is impossible. But NextEra Energy's increasingly ambitious plans for solar power in Florida are encouraging -- and might even hint at a way to ditch natural gas by midcentury.

Image source: Getty Images.

A win-win for investors and the environment

Xcel Energy made a bold public commitment to 100% carbon-free electricity by 2050. It was already well on its way, thanks in large part to geography: The company's four electric utilities operate in regions with some of the best wind and solar opportunities on the planet. While that gives it an edge over most peers, the improving economics of wind and solar suggest other electric utilities might not be too far behind in their pledges.

NextEra Energy is an obvious bet for the next company to announce a zero-carbon electricity pledge, even if its Florida-based utility faces unique challenges. That would provide certainty for investors on the long-term trajectory of the business and help the $85 billion company make good on plans to grow earnings and its dividend at a healthy rate for years to come.

Top 10 Value Stocks To Invest In Right Now

tags:CF,EMD,CPRX,AGEN,ADUS,UBSH,DVAX,MCFT,ZBH,SM,

Frontier Capital Management Co. LLC acquired a new position in Seattle Genetics, Inc. (NASDAQ:SGEN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 59,263 shares of the biotechnology company’s stock, valued at approximately $3,934,000.

Several other large investors have also recently made changes to their positions in SGEN. BlackRock Inc. raised its stake in shares of Seattle Genetics by 9.5% in the first quarter. BlackRock Inc. now owns 8,492,963 shares of the biotechnology company’s stock worth $444,521,000 after purchasing an additional 736,469 shares during the last quarter. Nexthera Capital LP purchased a new position in shares of Seattle Genetics in the first quarter worth about $18,998,000. Wells Fargo & Company MN raised its stake in shares of Seattle Genetics by 337.2% in the first quarter. Wells Fargo & Company MN now owns 306,681 shares of the biotechnology company’s stock worth $16,051,000 after purchasing an additional 236,538 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Seattle Genetics by 18.0% in the second quarter. First Trust Advisors LP now owns 1,042,574 shares of the biotechnology company’s stock worth $69,216,000 after purchasing an additional 159,401 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Seattle Genetics by 108.4% in the first quarter. UBS Group AG now owns 256,549 shares of the biotechnology company’s stock worth $13,428,000 after purchasing an additional 133,450 shares during the last quarter.

Top 10 Value Stocks To Invest In Right Now: CF Industries Holdings, Inc.(CF)

Advisors' Opinion:

• [By Max Byerly]

  CF Industries (NYSE:CF) had its target price trimmed by Bank of America from $40.00 to $38.00 in a report published on Friday. The brokerage currently has an underperform rating on the basic materials company’s stock.

• [By Joseph Griffin]

  Canaccord Genuity Group Inc (TSE:CF) Director Dvaipayan Ghose sold 20,000 shares of Canaccord Genuity Group stock in a transaction on Thursday, June 14th. The stock was sold at an average price of C$7.17, for a total transaction of C$143,400.00.

• [By Chris Lange]

  The stock posting the largest daily percentage loss in the S&P 500 ahead of the close was CF Industries Holdings, Inc. (NYSE: CF) which fell about 3% to $43.04. The stock's 52-week range is $27.27 to $46.20. Volume was about 2.6 million compared to the daily average volume of 2.6 million.

Top 10 Value Stocks To Invest In Right Now: Western Asset Emerging Markets Income Fund, Inc(EMD)

Advisors' Opinion:

• [By Joseph Griffin]

  Emerald Crypto (EMD) is a proof-of-work (PoW) coin that uses the
  Scrypt hashing algorithm. Its launch date was June 16th, 2013. Emerald Crypto’s total supply is 19,117,129 coins. Emerald Crypto’s official Twitter account is @Emerald_Crypto and its Facebook page is accessible here. Emerald Crypto’s official website is www.emeraldcrypto.de.

Top 10 Value Stocks To Invest In Right Now: Catalyst Pharmaceuticals, Inc.(CPRX)

Advisors' Opinion:

• [By Lisa Levin] Gainers Sigma Labs, Inc. (NASDAQ: SGLB) shares rose 90.9 percent to $2.52. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing. Oragenics, Inc. (NYSE: OGEN) shares surged 58.4 percent to $1.9005 after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study. Dick's Sporting Goods, Inc. (NYSE: DKS) shares climbed 23.2 percent to $37.5370 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook. Summer Infant, Inc. (NASDAQ: SUMR) rose 21.9 percent to $1.17 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital. TapImmune, Inc. (NASDAQ: TPIV) jumped 18.8 percent to $4.87. WBB Securities upgraded TapImmune from Speculative Buy to Buy. Movado Group, Inc. (NYSE: MOV) gained 17.2 percent to $49.45 after the company reported better-than-expected Q1 results and raised its guidance. ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) jumped 16.2 percent to $7.96. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating. Legacy Reserves LP (NASDAQ: LGCY) rose 15.5 percent to $5.6011. InspireMD, Inc. (NYSE: NSPR) gained 13.3 percent to $1.36 following PR announcing sustained benefit of CGuard EPS. Immutep Limited (NASDAQ: IMMP) shares climbed 13.2 percent to $2.7724 after the company reported new data from its ongoing TACTI-mel Phase I trial, which evaluated the combination of eftilagimod alpha, its lead compound, with Merck & Co., Inc. (NYSE: MRK)'s Keytruda in unresectable or metastatic melanoma patients, who have had a suboptimal response or had disease progression with keytruda monotherapy.. SpartanNash Co (NASDAQ: SPTN) rose 12.2 percent to $21.20 after the company reported upbeat earnings for its first quarter on Tuesday. Amtech Systems, Inc. (NASDAQ: ASYS) rose 12.1 percent to
• [By Joseph Griffin]

  Cantor Fitzgerald assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report issued on Thursday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $8.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 153.97% from the stock’s current price.

• [By Shane Hupp]

  Cantor Fitzgerald assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report issued on Thursday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $8.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 153.97% from the stock’s current price.

• [By Joseph Griffin]

  BidaskClub downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a sell rating to a strong sell rating in a report published on Wednesday morning.

• [By Stephan Byrd]

  BidaskClub cut shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a hold rating to a sell rating in a report published on Tuesday.

  CPRX has been the subject of several other research reports. HC Wainwright set a $6.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 22nd. Zacks Investment Research raised Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $3.25 target price for the company in a research report on Monday, August 13th. Oppenheimer started coverage on Catalyst Pharmaceuticals in a research report on Thursday, July 12th. They issued a buy rating and a $6.00 target price for the company. Cantor Fitzgerald started coverage on Catalyst Pharmaceuticals in a research report on Friday, September 21st. They issued an overweight rating for the company. Finally, Piper Jaffray Companies started coverage on Catalyst Pharmaceuticals in a research report on Friday, September 7th. They issued an overweight rating and a $5.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $5.61.

• [By Joseph Griffin]

  Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) have received a consensus rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $6.25.

Top 10 Value Stocks To Invest In Right Now: Agenus Inc.(AGEN)

Advisors' Opinion:

• [By Shane Hupp]

  Shares of Agenus (NASDAQ:AGEN) dropped 9.8% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $3.30 and last traded at $3.32. Approximately 2,421,286 shares changed hands during mid-day trading, an increase of 53% from the average daily volume of 1,586,724 shares. The stock had previously closed at $3.68.

• [By George Budwell]

  Shares of the small-cap biotech Agenus (NASDAQ:AGEN) reversed its year-long down trend by gaining a stately 20.1% last month, according to data from S&P Global Market Intelligence. What sparked this marked turnaround?

• [By George Budwell]

  The small-cap immuno-oncology company Agenus (NASDAQ:AGEN) and the inhaled insulin company MannKind Corporation (NASDAQ:MNKD) are prime examples of this phenomenon. Even though both of these companies have been in existence for over two decades, these two particular biotechs have failed to bring a product to market capable of generating a significant revenue stream. As a result, these two companies have essentially been forced to wipe out their early shareholders through serial dilution.

• [By Cory Renauer]

  Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical trials.

Top 10 Value Stocks To Invest In Right Now: Addus HomeCare Corporation(ADUS)

Advisors' Opinion:

• [By Ethan Ryder]

  BidaskClub upgraded shares of Addus Homecare (NASDAQ:ADUS) from a buy rating to a strong-buy rating in a report published on Saturday.

  Several other equities analysts have also recently weighed in on the stock. Stephens set a $56.00 price target on shares of Addus Homecare and gave the company a buy rating in a research report on Monday, April 2nd. Robert W. Baird set a $43.00 price target on shares of Addus Homecare and gave the company a hold rating in a research report on Wednesday, March 14th. ValuEngine raised shares of Addus Homecare from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Addus Homecare from a buy rating to a strong sell rating in a research report on Monday, June 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $51.00.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Addus Homecare (ADUS)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Addus HomeCare (NASDAQ:ADUS) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

Top 10 Value Stocks To Invest In Right Now: Union Bankshares Corporation(UBSH)

Advisors' Opinion:

• [By Shane Hupp]

  Union Bankshares (NASDAQ:UBSH) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report issued on Thursday.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Union Bankshares (UBSH)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Motley Fool Staff]

  Union First Market Bankshares (NASDAQ:UBSH) Q2 2018 Earnings Conference CallJul. 18, 2018 9:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator 

• [By Shane Hupp]

  Union Bankshares (NASDAQ:UBSH) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Thursday.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Union Bankshares (UBSH)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks To Invest In Right Now: Dynavax Technologies Corporation(DVAX)

Advisors' Opinion:

• [By George Budwell]

  Shares of immuno-oncology and next-generation vaccine-maker Dynavax Technologies Corporation (NASDAQ:DVAX) lost 10.5% of their value in September, according to data from S&P Global Market Intelligence. What went wrong for the drugmaker last month?

• [By Lisa Levin] Gainers ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share. Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook. vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June. Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results. RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million. Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter. Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales. Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings. MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma. New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor. Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session. Himax Technologies, Inc. (NASDAQ: HIMX) shares rose
• [By Joseph Griffin]

  Dynavax Technologies (NASDAQ:DVAX) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

• [By Neha Chamaria, George Budwell, and Rich Duprey]

  Each of these situations -- and more like them -- could throw up great opportunities for long-term investors. Not one to miss them, we asked three Motley Fool contributors to hunt up an unappreciated stock that they believe deserves more love. They came up with some really interesting names, including Illinois Tool Works (NYSE:ITW), ShotSpotter (NASDAQ:SSTI), and Dynavax Technologies Corporation (NASDAQ:DVAX).

Top 10 Value Stocks To Invest In Right Now: MCBC Holdings, Inc.(MCFT)

Advisors' Opinion:

• [By Shane Hupp]

  Paloma Partners Management Co trimmed its position in MCBC Holdings Inc (NASDAQ:MCFT) by 14.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 15,754 shares of the company’s stock after selling 2,715 shares during the quarter. Paloma Partners Management Co’s holdings in MCBC were worth $456,000 as of its most recent SEC filing.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on MCBC (MCFT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Lisa Levin] Gainers The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance. WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results. MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast. Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39. Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results. ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings. Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million. Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results. Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results. VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71. Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results. Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results. Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results. Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739. Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69
• [By Ethan Ryder]

  MCBC Holdings (NASDAQ:MCFT) shares reached a new 52-week high and low during trading on Wednesday . The company traded as low as $30.42 and last traded at $30.27, with a volume of 14269 shares changing hands. The stock had previously closed at $29.28.

• [By Ethan Ryder]

  Shares of MCBC Holdings Inc (NASDAQ:MCFT) have received an average rating of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $28.08.

Top 10 Value Stocks To Invest In Right Now: Zimmer Biomet Holdings, Inc.(ZBH)

Advisors' Opinion:

• [By Max Byerly]

  Zimmer Biomet Holdings Inc (NYSE:ZBH) – Investment analysts at Oppenheimer lowered their Q3 2018 earnings estimates for Zimmer Biomet in a research note issued on Monday, July 30th. Oppenheimer analyst S. Lichtman now anticipates that the medical equipment provider will post earnings of $1.59 per share for the quarter, down from their previous estimate of $1.72. Oppenheimer has a “Buy” rating and a $138.00 price target on the stock. Oppenheimer also issued estimates for Zimmer Biomet’s Q4 2018 earnings at $2.22 EPS, FY2018 earnings at $7.64 EPS and FY2019 earnings at $7.97 EPS.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Massachusetts Financial Services Co. MA trimmed its holdings in shares of Zimmer Biomet (NYSE:ZBH) by 8.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 15,053,800 shares of the medical equipment provider’s stock after selling 1,404,161 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.07% of Zimmer Biomet worth $1,641,467,000 at the end of the most recent quarter.

• [By Joseph Griffin]

  Adviser Investments LLC acquired a new stake in Zimmer Biomet (NYSE:ZBH) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,318 shares of the medical equipment provider’s stock, valued at approximately $144,000.

• [By Max Byerly]

  Zimmer Biomet Holdings Inc (NYSE:ZBH) has been given a consensus rating of “Buy” by the thirty research firms that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $135.86.

• [By Stephan Byrd]

  IBM Retirement Fund trimmed its stake in shares of Zimmer Biomet (NYSE:ZBH) by 12.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,444 shares of the medical equipment provider’s stock after selling 620 shares during the period. IBM Retirement Fund’s holdings in Zimmer Biomet were worth $485,000 at the end of the most recent reporting period.

Top 10 Value Stocks To Invest In Right Now: SM Energy Company(SM)

Advisors' Opinion:

• [By Stephan Byrd]

  SM Energy (NYSE:SM) – Equities research analysts at Seaport Global Securities lifted their Q2 2018 earnings per share estimates for shares of SM Energy in a research report issued on Wednesday, May 23rd. Seaport Global Securities analyst M. Kelly now anticipates that the energy company will post earnings per share of ($0.08) for the quarter, up from their prior forecast of ($0.09). Seaport Global Securities also issued estimates for SM Energy’s Q3 2018 earnings at $0.00 EPS, FY2018 earnings at $0.06 EPS, Q1 2019 earnings at $0.00 EPS, Q2 2019 earnings at $0.06 EPS, Q3 2019 earnings at $0.35 EPS, Q4 2019 earnings at $0.48 EPS and FY2019 earnings at $0.89 EPS.

• [By Logan Wallace]

  Scotia Howard Weill upgraded shares of SM Energy (NYSE:SM) from a sector perform rating to a sector outperform rating in a research note published on Thursday morning.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on SM Energy (SM)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Heal Care Stocks To Buy Right Now

tags:NBLX,SFLY,JASO,HMY,CMRE,AIRT,MYOK,TAL,PROV,PLX, A federal judge approved $75 million worth of loans to Remington so the company can keep making guns as it works through bankruptcy, according to court documents.

The firearms company filed for Chapter 11 bankruptcy protection earlier this week after more than 200 years in business.

The loan will allow Remington to continue pursuing a deal to cut as much as $620 million in debt. The company succumbed to a plunge in demand for guns that has dragged down the industry.

Remington has asked for loans totaling $338 million to be approved by April 29, but only a portion has been approved so far.

The $75 million loan approved on Tuesday is the "interim amount to get them through the interim period until they get to that final hearing on the additional amount that they're going to need," said Sarah Foss, legal analyst at Debtwire.

Founded in New York in 1816, Remington is one of the oldest gunmakers in America, and one of the most iconic gun brands in the world. The company, which is based in North Carolina, makes a variety of rifles, handguns and shotguns through its seven plants, including a sprawling brick factory in Ilion, NY, that's been churning out guns since the 1840s.

Top 10 Heal Care Stocks To Buy Right Now: Noble Midstream Partners LP (NBLX)

Advisors' Opinion:

• [By Matthew DiLallo]

  Noble Midstream Partners (NYSE:NBLX) operates more traditional energy assets such as oil and gas pipelines and related infrastructure. Long-term contracts also underpin Noble Midstream's assets, providing it with a predictable cash flow stream. That money currently supports the company's 4.4% yielding distribution.

• [By Matthew DiLallo]

  Noble Midstream (NYSE:NBLX) has a bold plan to grow its already impressive 7.4%-yielding distribution to investors by 20% per year all the way through 2022, which is one of the fastest rates in the midstream sector. Driving that growth would be the expansion of the company's oil and gas gathering system to support the anticipated increase in production from customers like its parent, Noble Energy (NYSE:NBL).

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Noble Midstream Partners (NBLX)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Matthew DiLallo]

  Noble Midstream Partners (NYSE:NBLX) is one of more than a half dozen midstream master limited partnerships (MLPs) formed in recent years by exploration and production (E&P) companies to facilitate their growth. However, while Noble Midstream shares a similar heritage with these peers, it's in a league of its own when it comes to financial strength and distribution growth potential. That makes it quite a compelling option for investors seeking both growth and income.

• [By Matthew DiLallo]

  Two great dividend growth stocks to consider are Antero Midstream Partners (NYSE:AM) and Noble Midstream Partners (NYSE:NBLX). These two pipeline companies are on pace to double their dividend rates over the next five years. That high-octane dividend growth, when combined with their high yields, could give them the fuel to significantly outpace the market in the coming years.

Top 10 Heal Care Stocks To Buy Right Now: Shutterfly Inc.(SFLY)

Advisors' Opinion:

• [By Logan Wallace]

  Shutterfly, Inc. (NASDAQ:SFLY) SVP Ishantha Lokuge sold 2,514 shares of the stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $72.73, for a total transaction of $182,843.22. Following the sale, the senior vice president now directly owns 2,514 shares in the company, valued at approximately $182,843.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Shutterfly (SFLY)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  American Century Companies Inc. lifted its holdings in shares of Shutterfly, Inc. (NASDAQ:SFLY) by 208.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 324,834 shares of the technology company’s stock after buying an additional 219,679 shares during the quarter. American Century Companies Inc. owned about 0.98% of Shutterfly worth $29,245,000 at the end of the most recent quarter.

Top 10 Heal Care Stocks To Buy Right Now: JA Solar Holdings, Co., Ltd.(JASO)

Advisors' Opinion:

• [By Ethan Ryder]

  JA Solar (NASDAQ:JASO) is scheduled to be posting its quarterly earnings results before the market opens on Monday, July 2nd. Analysts expect JA Solar to post earnings of $0.20 per share for the quarter.

• [By Garrett Baldwin]

  According to Money Morning Capital Wave Strategist Shah Gilani, we shouldn't be surprised. Here's what you need to know to stay out ahead of the next major crash.

  Four Stocks to Watch Today: DIS, JASO, AAPL, GOOGL Shares of The Walt Disney Co. (NYSE: DIS) are in focus thanks to a record-breaking weekend for its Pixar division. The company's film "Incredibles 2" collected a staggering $180 million during its first weekend in the domestic box office. The massive windfall is the largest opening weekend for an animated film and easily topped the studios previous record for "Finding Dory" ($135.1 million). The e-commerce wars are heating up in China. This morning, Alphabet Inc. (Nasdaq: GOOGL) – the owner of Google – announced it would purchase a $550 million stake in com Inc. (Nasdaq: JD), a Chinese e-commerce firm and primary rival to Alibaba Group Holding Ltd. (NYSE: BABA). Apple Inc. (Nasdaq: AAPL) announced it has inked a multiyear deal with Oprah Winfrey to create original content for the company's television division. The deal is the largest content partnership in Apple's history. The company is trying to compete with rivals Netflix Inc. (Nasdaq: NFLX), com Inc. (Nasdaq: AMZN), and Time Warner Inc.'s (NYSE: TMX) HBO division. Winfrey is expected to create new shows and to appear on screen. "Together, Winfrey and Apple will create original programs that embrace her incomparable ability to connect with audiences around the world," the company said in a statement. Look for an earnings report from JA Solar Holdings Co. Ltd. (Nasdaq: JASO). Wall Street expects the renewable energy giant will report earnings per share of $0.02 on top of $593 million in revenue.

  Follow Money Morning on Twitter, Facebook, and LinkedIn.

• [By Garrett Baldwin]
  This morning, President Trump suggested that the United States is considering strong military action in response to recent chemical attacks carried out on civilians by the Syrian government. The president promised to send "nice and new and 'smart'" missiles to Syria and accused the Russian government of partnering with a "Gas Killing Animal who kills his people and enjoys it!" The president's remarks are a significant departure from comments made last week, which suggested that the United States would be pulling out of Syria in the coming months. Trump's threat of war over a recent chemical attack in Syria drove crude oil and gold prices higher. Geopolitical worries often offer a boost to commodity prices due to concerns about supply. Trump's threat comes at a time that markets are already concerned about a significant military conflict in the Middle East between Saudi Arabia and Iran. WTI crude prices added 0.9% to hit $66.10 per barrel. Brent crude pushed to $71.10 per barrel. Gold price topped $1,350 per ounce and are poised for bigger gains. According to Axios, U.S. Speaker of the House Paul Ryan (R-WI) has privately told friends that he will not seek reelection in the fall. The news comes at a perilous time for Republicans, who are expected to lose the House of Representatives and potentially the Senate. Axios was the first to report the news. The story is also notable because Ryan recently achieved his long-time goal of passing tax reform in late 2017. Four Stocks to Watch Today: FB, FOXA, CBS Shares of Twenty-First Century Fox Inc. (NYSE: FOXA) fell in pre-market hours on news that investigators from the European Commission raided the firm's London office yesterday. Reports indicate that investigators are trying to keep their goals confidential. However, there has been a lot of scrutiny over Rupert Murdoch's goal to purchase rival Sky in recent months. British authorities have argued that this deal would not be in the public's best interest. Accor
• [By Garrett Baldwin]

  Now is the time to act. Get out in front of the green wave, and own this stock. It's legal. The recommendation is free. And you have the opportunity to become a "Marijuana Millionaire" with very little risk. Here's the pick.

  The Top Stock Market Stories for Monday Tariffs are overshadowing the start of earnings season. This week, a variety of Wall Street banks, consumer goods, and airline companies report for the previous quarter. While profits are expected to remain strong, the outlook for the rest of the year is expected to take into account the impact of tariffs on global trade. This is likely to weigh on investor sentiment. According to a report from real estate giant REIS Inc., mall vacancies have hit a six-year high at 8.6% last quarter. The fall of brick-and-mortar stores has been fueled by the rise of Amazon.com Inc. (Nasdaq: AMZN), which continues to see its stock surge to new highs. It's not too late to get in on Amazon at a fraction of the cost of today's shares. We'll show you how… right here. Speaking of Amazon, the e-commerce giant recently made a big splash in the pharmacy benefits business after its purchase of online benefits provider PillPack. This purchase has many analysts convinced that Amazon is about to do to pharmacies what it has done to malls over the last decade. And while Amazon is going to be a major player in the drug-delivery business in the future, there is one stock that is going to stave off any further attack from Amazon and the delivery business. Best of all, this stock has an incredible VQScore, and it's trading at a huge discount. Three Stocks to Watch Today: HOG, TM, TWTR A number of companies are reporting that earnings could have a dramatic impact on their future balance sheets. That's especially true in the transportation business. Harley-Davidson Inc. (NYSE: HOG) has said the tariffs will cost up to $100 million per year and add $2,200 per vehicle. Now, Toyota Motor Corp. (NYSE: TM) has said the tariffs wi
• [By Travis Hoium]

  The impact will have ripple effects across the industry. Major manufacturers like Canadian Solar (NASDAQ:CSIQ), JinkoSolar (NYSE:JKS), Hanwha Q Cells (NASDAQ:HQCL), and JA Solar (NASDAQ:JASO) will see margins squeezed as volume and sales prices fall. They were all enjoying higher margins and strong demand in early 2018, so the could reverse to net losses later this year. 

• [By Rich Smith]

  Fearing that prospects for the solar industry are dimming, yesterday analysts at Roth Capital bailed on the solar industry wholesale, downgrading shares of Hanwha Q Cells, JA Solar Holdings (NASDAQ:JASO), and ReneSola to sell. This morning, Merrill Lynch showed signs it's planning to join the rush to the exits as well, downgrading American solar manufacturer First Solar (NASDAQ:FSLR) to neutral.

Top 10 Heal Care Stocks To Buy Right Now: Harmony Gold Mining Company Limited(HMY)

Advisors' Opinion:

• [By WWW.GURUFOCUS.COM]

  For the details of Exor Investments (UK) LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Exor+Investments+%28UK%29+LLP

  These are the top 5 holdings of Exor Investments (UK) LLPSibanye-Stillwater (SBGL) - 45,970,311 shares, 32.51% of the total portfolio. Shares added by 8.09%VEON Ltd (VEON) - 37,657,792 shares, 31.02% of the total portfolio. Shares added by 3.83%Cameco Corp (CCJ) - 5,967,410 shares, 19.32% of the total portfolio. Harmony Gold Mining Co Ltd (HMY) - 13,275,728 shares, 6.26% of the total portfolio. Shares added by 6.84%Novagold Resources Inc (NG) - 5,889,905 shares, 6.21% of the total portfolio. Shares
• [By Maxx Chatsko]

  Tensions keep rising in the South African mining sector. Today that's taking a toll on shares of companies with major mining operations in the country. Sibanye-Stillwater (NYSE:SBGL) stock fell by as much as 13.4%, Gold Fields Limited (NYSE:GFI) stock dropped by as much as 12.3%, and Harmony Gold Mining Co. (NYSE:HMY) fell by as much as 9.9%. Others such as AngloGold Ashanti, Anglo American, and Randgold Resources also saw significant declines in their share prices.

• [By Paul Ausick]

  Harmony Gold Mining Co. (NYSE: HMY) fell 1.9% Tuesday to match a 52-week low of $1.56 set Monday. Shares closed at $1.59 yesterday. The 52-week high is $2.53. Volume of around 4 million was nearly 15% lower than the daily average of about 4.5 million. The company had no specific news.

• [By Ethan Ryder]

  ValuEngine cut shares of Harmony Gold Mining (NYSE:HMY) from a sell rating to a strong sell rating in a research report report published on Wednesday.

Top 10 Heal Care Stocks To Buy Right Now: Costamare Inc.(CMRE)

Advisors' Opinion:

• [By Shane Hupp]

  Get a free copy of the Zacks research report on COSTAMARE Inc/SH (CMRE)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  COSTAMARE Inc/SH (NYSE:CMRE) has received an average recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $7.75.

• [By Rich Smith]

  Shares of three big oceangoing container-shipping companies -- Triton International (NYSE:TRTN), Seaspan (NYSE:SSW), and Costamare (NYSE:CMRE) -- suffered huge losses in early trading Friday after Wells Fargo announced it was downgrading "the entire container complex," as StreetInsider.com put it.

Top 10 Heal Care Stocks To Buy Right Now: Air T, Inc.(AIRT)

Advisors' Opinion:

• [By Logan Wallace]

  News articles about Air T (NASDAQ:AIRT) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Air T earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the transportation company an impact score of 46.6995978620286 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top 10 Heal Care Stocks To Buy Right Now: MyoKardia, Inc.(MYOK)

Advisors' Opinion:

• [By Logan Wallace]

  Myokardia Inc (NASDAQ:MYOK) insider June Lee sold 5,000 shares of the stock in a transaction dated Friday, September 21st. The shares were sold at an average price of $63.13, for a total value of $315,650.00. Following the completion of the transaction, the insider now directly owns 5,426 shares of the company’s stock, valued at approximately $342,543.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

• [By Shane Hupp]

  Get a free copy of the Zacks research report on MyoKardia (MYOK)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  Tortoise Investment Management LLC lowered its position in Myokardia Inc (NASDAQ:MYOK) by 33.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,265 shares of the biotechnology company’s stock after selling 1,133 shares during the quarter. Tortoise Investment Management LLC’s holdings in Myokardia were worth $112,000 as of its most recent SEC filing.

Top 10 Heal Care Stocks To Buy Right Now: TAL International Group Inc.(TAL)

Advisors' Opinion:

• [By Ethan Ryder]

  TAL Education Group (NYSE:TAL) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

• [By Dustin Parrett]

  Our analysis from May 2013 found the VQScore tool identified 48 triple-digit winners, including a staggering 2,573% gainer in TAL Education Group ADR (NYSE: TAL).

• [By Paul Ausick]

  Tal Education Group (NYSE: TAL) traded down about 4.8% Thursday and posted a new 52-week low of $24.86 after closing Wednesday at $26.10. The stock’s 52-week high is $47.63. Volume was about 20% above the daily average of around 6.1 million. The company had no specific news.

• [By Ethan Ryder]

  Tarena International (NASDAQ: TEDU) and TAL Education (NYSE:TAL) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

• [By Stephan Byrd]

  Shares of TAL Education Group (NYSE:TAL) have earned an average rating of “Hold” from the eight brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $49.00.

Top 10 Heal Care Stocks To Buy Right Now: Provident Financial Holdings, Inc.(PROV)

Advisors' Opinion:

• [By Max Byerly]

  News articles about Provident Financial (NASDAQ:PROV) have been trending somewhat negative this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Provident Financial earned a daily sentiment score of -0.02 on Accern’s scale. Accern also assigned news articles about the financial services provider an impact score of 45.9215692366566 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

• [By Ethan Ryder]

  E*TRADE Financial (NASDAQ: ETFC) and Provident Financial (NASDAQ:PROV) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

• [By Logan Wallace]

  Charter Financial (NASDAQ: CHFN) and Provident Financial (NASDAQ:PROV) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Top 10 Heal Care Stocks To Buy Right Now: Protalix BioTherapeutics, Inc.(PLX)

Advisors' Opinion:

• [By Stephan Byrd]

  ILLEGAL ACTIVITY NOTICE: “Protalix Biotherapeutics (PLX) Shares Up 6.8%” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3355139/protalix-biotherapeutics-plx-shares-up-6-8.html.

• [By Ethan Ryder]

  PlexCoin (CURRENCY:PLX) traded up 3.9% against the U.S. dollar during the 24-hour period ending at 19:00 PM ET on June 1st. In the last week, PlexCoin has traded down 26% against the U.S. dollar. One PlexCoin token can currently be bought for approximately $0.0095 or 0.00000126 BTC on major exchanges including Cryptopia and CoinExchange. PlexCoin has a total market capitalization of $0.00 and approximately $27.00 worth of PlexCoin was traded on exchanges in the last day.

• [By Stephan Byrd]

  PlexCoin (CURRENCY:PLX) traded flat against the US dollar during the 24-hour period ending at 19:00 PM Eastern on August 24th. One PlexCoin token can currently be bought for about $0.0074 or 0.00000111 BTC on popular exchanges. Over the last week, PlexCoin has traded flat against the US dollar. PlexCoin has a total market cap of $0.00 and $7.00 worth of PlexCoin was traded on exchanges in the last 24 hours.

• [By Shane Hupp]

  Shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) saw strong trading volume on Wednesday . 3,171,206 shares changed hands during mid-day trading, an increase of 375% from the previous session’s volume of 667,423 shares.The stock last traded at $0.62 and had previously closed at $0.52.

• [By Joseph Griffin]

  PlexCoin (CURRENCY:PLX) traded 1.5% higher against the US dollar during the 1-day period ending at 13:00 PM Eastern on June 19th. PlexCoin has a total market cap of $0.00 and approximately $0.00 worth of PlexCoin was traded on exchanges in the last day. In the last week, PlexCoin has traded up 9.7% against the US dollar. One PlexCoin token can currently be purchased for $0.0067 or 0.00000099 BTC on popular cryptocurrency exchanges including CoinExchange and Cryptopia.